What the FDA's Briefing Documents Actually Say About Each of the Seven Peptides Going to PCAC

On Monday and Tuesday June 29-30, 2026, FDA career-staff scientists released their briefing documents for the July 23-24 Pharmacy Compounding Advisory Committee meeting and concluded none of the seven peptides under review has sufficient evidence to support 503A bulks list eligibility. The seven substances are BPC-157, KPV, TB-500 (thymosin beta-4 fragment), MOTS-c, Emideltide (delta sleep-inducing peptide, DSIP), Semax, and Epitalon. The briefing recommendation explicitly covers both the free-base forms and acetate salts of each compound.

The recommendation directly contradicts HHS Secretary RFK Jr.'s public position that the April 23 Category 2 removals were meant to clear the path for 503A addition. Coverage ran across NBC News, NPR, Washington Post, KPBS, and STAT News (which also broke the parallel scoop on the eight new panelists named to PCAC, the majority with peptide industry ties).

This piece walks through what the briefing actually says about each of the seven peptides, the four recurring categories of FDA concern that appear across the documents, and what the product-quality testing data shows for compounded preparations sampled from the channel. The substance-by-substance evidence picture is what the panel will weigh July 23-24, regardless of how the conflicts-of-interest question shakes out.

The briefing documents organize the staff position across four categories that appear for each of the seven peptides, with the relative weight shifting by substance.

Inadequate safety data. The FDA's standard for 503A bulks list addition includes a demonstration that the substance has acceptable risk for the intended compounding use. For the seven peptides, the briefing concludes there is not enough human safety data to support that demonstration. Most of the safety profile rests on animal studies (predominantly rodent) and small, often uncontrolled human series.

Characterization and impurity concerns. The briefing flags concerns about whether compounding-channel preparations consistently contain what the label claims. FDA testing of compounded product samples turned up heavy-metal contamination, microbial contamination, and mislabeled contents (vials testing well above or well below the labeled peptide concentration). The agency's position is that the active pharmaceutical ingredient (API) supply chain feeding compounding pharmacies cannot be relied upon for consistent quality.

Immunogenicity risk. The FDA presented adverse event data showing immune reactions to peptide preparations. The concern applies particularly to non-naturally-occurring peptides (BPC-157, MOTS-c at therapeutic doses) and to peptides whose immunogenicity has not been formally characterized in humans (most of the seven). The agency cited Form FDA 3500 voluntary adverse event reports from the post-Category-2 period.

Lack of historical-use evidence meeting bulks-list criteria. The 503A bulks list standard requires evidence of historical compounding-pharmacy use sufficient to justify the substance's inclusion. The briefing concludes that for several of the substances (particularly Epitalon and MOTS-c), the US compounding-pharmacy use history is too thin to meet the criteria, and that the historical use that does exist is primarily through unregulated research-chemical channels rather than licensed 503A practice.

BPC-157 is the most-discussed peptide on the list and has the most extensive preclinical evidence base. The synthetic 15-amino-acid peptide derived from body protection compound has roughly 200 published animal studies from the University of Zagreb laboratory of Predrag Sikiric, covering tendon-to-bone healing, gastric mucosal protection, and vascular regeneration in rodents.

The FDA briefing acknowledges the preclinical depth but lands on three concerns. First, human evidence is limited to a small open-label inflammatory bowel disease pilot and case-report literature; no completed Phase 3 trial exists in any indication. Second, BPC-157 is not a naturally occurring peptide in the human body (the parent body protection compound is, but the 15-amino-acid pentadecapeptide fragment is synthetic), which raises the immunogenicity baseline. Third, FDA testing of compounded BPC-157 product samples found inconsistent purity and content, with some vials containing well below the labeled concentration.

The briefing also notes that the proposed clinical use for the PCAC submission (ulcerative colitis) is narrower than the broader sports-medicine and tendon-recovery uses driving consumer demand. The committee will vote on the nominated indication, not the off-label uses. Even if the vote came in affirmative on ulcerative colitis, that would not authorize 503A compounding for sports-medicine applications. The FDA staff conclusion: insufficient evidence.

KPV is the tripeptide lysine-proline-valine, the C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). The proposed compounding use is for inflammatory conditions including inflammatory bowel disease and atopic dermatitis.

The FDA briefing notes that KPV has shown anti-inflammatory activity in mouse colitis models and in vitro work on melanocortin-1-receptor signaling. The human evidence is the thinnest on the list: a small number of case reports and open-label series, no controlled trials. Because KPV is a naturally occurring fragment of an endogenous peptide, the immunogenicity baseline is lower than for synthetic novel sequences. The product-quality testing found fewer contamination issues for KPV-labeled product than for some of the other substances, suggesting the supply chain is somewhat more reliable.

The briefing's KPV conclusion turns primarily on the effectiveness factor: with no controlled human trial, the agency cannot verify that the substance does what the nominator claims it does. Some PCAC observers have noted that KPV may be the most likely of the seven to receive a split or affirmative vote on safety grounds, while still failing the effectiveness bar.

TB-500 is the brand and research name commonly applied to a synthetic active fragment of thymosin beta-4, a 43-amino-acid actin-sequestering peptide naturally found in human serum. The substance under PCAC review is the synthetic fragment, not full-length thymosin beta-4. The proposed compounding use is tissue repair, including tendon and ligament injury recovery, wound healing, and cardiac tissue repair.

The FDA briefing notes the mechanistic plausibility of the actin-sequestration story but cites three problems. First, the synthetic fragment (TB-500 as sold) is not identical to the full-length thymosin beta-4 that RegeneRx Biopharmaceuticals ran through several Phase 2 trials in dry eye, neurotrophic keratitis, and pressure ulcers in the 2010s. The Phase 2 evidence from RegeneRx applies to the full-length peptide, not the fragment.

Second, no completed Phase 3 trial of TB-500 (the fragment) in any human indication exists. Third, TB-500 is on the World Anti-Doping Agency's prohibited list for horse racing because of its actin-sequestration and angiogenesis-promotion mechanism, raising sport-integrity concerns that overlap with the safety question for human use.

The FDA staff conclusion on TB-500 is insufficient evidence on both safety and effectiveness, with a particular concern that the marketed compound is mechanistically related to but chemically distinct from the substance that has been studied in Phase 2.

MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded by the 12S ribosomal RNA gene in mitochondrial DNA. The proposed compounding use is obesity and osteoporosis. The substance has the strongest mechanistic story on the list: published work from the Cohen laboratory at USC and other academic groups shows MOTS-c modulates AMP-activated protein kinase (AMPK) signaling, improves insulin sensitivity in mice, and protects against age-related metabolic decline.

The FDA briefing acknowledges the mechanism but lands on three concerns. First, human trial data is limited to an early-stage HIV-associated lipodystrophy program with limited published outcomes and ongoing early-stage obesity work; no completed Phase 3 trial exists. Second, MOTS-c is naturally produced in mitochondria but the synthetic version dosed therapeutically (typically 10 mg subcutaneous twice weekly) is well above physiological levels, raising immunogenicity and off-target effect concerns at supraphysiological exposures. Third, the historical 503A compounding-pharmacy use base for MOTS-c is thin; most US distribution has run through research-chemical channels rather than licensed pharmacy practice.

The FDA staff conclusion: insufficient evidence on the human-trial side, even with a stronger mechanistic story than several of the other substances.

Emideltide is the modern naming convention for delta sleep-inducing peptide (DSIP), a 9-amino-acid neuropeptide first isolated by Schoenenberger and Monnier from rabbit cerebral venous blood in 1977. The proposed compounding use is sleep disorders.

DSIP has the longest historical-use claim on the list (nearly 50 years of European research, particularly Swiss and Russian institutions). The FDA briefing acknowledges the historical depth but lands on two concerns. First, the placebo-controlled clinical trials from the 1980s and 1990s evaluating DSIP for insomnia, chronic pain, and opioid withdrawal are small, often underpowered, and use measurement methods that do not always translate to current sleep-medicine endpoints. The cleanest published data is in opioid-detoxification adjunct use; the sleep-disorder data is suggestive but underpowered. Second, the historical compounding-pharmacy use of DSIP in US practice is thin; the substance's distribution has primarily been through research-chemical channels.

DSIP has perhaps the strongest case on the historical-use criterion among the seven substances but the weakest case on modern controlled-trial evidence. The FDA staff conclusion: insufficient evidence on the trial side, even with the historical depth.

Semax is a heptapeptide synthesized from the ACTH(4-10) fragment with a tetrapeptide tail. Developed in the Soviet Union in the 1980s and approved in Russia in 2011 for ischemic stroke recovery and cognitive disorders. The proposed US compounding use is cognitive function. The substance is on the Russian Vital and Essential Drugs list, giving it a substantial Russian prescriber history.

The FDA briefing addresses the Russian evidence directly. The agency acknowledges the Russian-language clinical research literature on Semax in ischemic stroke recovery, transient ischemic attack, and pediatric cognitive applications, but the briefing characterizes the trials as typically not blinded, small, and using measurement methods that do not translate cleanly to Western neurology endpoints. The substance is not FDA-approved as a drug in any indication.

Additional concerns: the intranasal delivery format used for cognitive applications has not been formally characterized for systemic exposure in US studies; the long-term safety database from Russian practice has not been transferred to FDA review; and the historical 503A compounding-pharmacy use base in the US is thin.

The FDA staff conclusion on Semax: insufficient evidence by FDA-grade trial standards, even with substantial Russian prescriber experience. The PCAC vote on Semax will partly turn on how the committee weighs non-US-approved drug practice.

Epitalon (also Epithalon) is a tetrapeptide (alanine-glutamate-aspartate-glycine) developed by Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology in the 1980s as a synthetic version of an extract isolated from the pineal gland. The proposed compounding use is 'healthy aging,' specifically telomerase activation and circadian regulation.

The FDA briefing addresses Epitalon last and most skeptically. The agency's concerns: the Khavinson laboratory has produced small, often uncontrolled clinical studies in the 2000s claiming telomerase activation, melatonin normalization, and reduced age-related mortality in elderly patients; the studies have not been replicated by independent Western groups; the longevity-claim aging cohort studies rest on a single research group, which the briefing flags as a structural evidence weakness; and the substance is one of the most aggressively marketed longevity peptides in the gray market and on social media, with marketing claims (telomerase activation, lifespan extension) that go well beyond the published evidence.

The historical 503A compounding-pharmacy use base for Epitalon in the US is thin; most distribution has run through research-chemical channels. The product-quality testing found inconsistent purity and content in compounded Epitalon samples.

The FDA staff conclusion: insufficient evidence on every factor, with the gap between marketing claims and published evidence the widest of the seven substances.

The briefing documents include results from FDA's testing of compounded peptide product samples obtained through the compounding-channel supply chain. Three categories of findings appear.

Heavy-metal contamination. Some samples contained elemental impurities above the US Pharmacopeia (USP <232>) limits for parenteral drug products. The contamination likely originates from the active pharmaceutical ingredient supply chain rather than the compounding step itself; the briefing flags this as evidence that the API supply for these substances has not been adequately controlled.

Microbial contamination. Some samples failed USP <71> sterility testing, with bacterial or fungal growth recovered from vials labeled as sterile injectable preparations. Sterility failure in injectable preparations is a serious safety concern with potential for systemic infection.

Mislabeled contents. Some samples tested well below the labeled peptide concentration, and a smaller number tested above. Sub-potent product means patients are not receiving the dose the prescriber ordered; super-potent product creates dosing-error risk. Independent testing in the broader research-chemical market has found similar patterns; the briefing's contribution is to extend the finding to compounding-pharmacy preparations.

The agency's broader argument: even if the underlying substance had adequate safety and effectiveness data, the compounding-channel supply chain is not currently producing consistent-quality product. Adding any of the seven to the 503A bulks list under current conditions would not solve the quality problem.

The FDA staff briefing is advisory to the committee, not binding. The PCAC will hear nominator presentations (typically from compounding-pharmacy industry groups), public oral testimony, written-comment summaries, and the staff briefing, then vote on each substance individually.

Historically, PCAC votes have followed staff briefings on roughly two-thirds of substance reviews, with the committee diverging from staff position when the substance has either a strong historical-use claim (DSIP, Semax) or a strong mechanistic story plus academic-research support (MOTS-c). The current panel composition (the eight new panelists named Monday, the majority with peptide industry ties) is the variable that may push outcomes away from the staff recommendation.

Substance-by-substance probability framing (analyst consensus rather than official prediction):

• BPC-157: Insufficient-evidence verdict likely; some chance of affirmative on safety grounds given preclinical depth
• KPV: Mixed; the lowest-profile substance with the thinnest evidence may receive procedural deferral
• TB-500: Insufficient-evidence verdict likely; the fragment-vs-full-length distinction is the operational challenge
• MOTS-c: Mixed; the strongest mechanistic story plus ongoing academic work could push toward affirmative
• DSIP: Mixed; the 50-year historical-use claim may carry weight even without trial evidence
• Semax: Mixed; how the panel weighs Russian prescriber history is the key variable
• Epitalon: Insufficient-evidence verdict likely; the gap between marketing and evidence is widest

The FDA makes the final administrative decision after the PCAC vote, typically within 4 to 12 months. A PCAC affirmative vote that the FDA overrides is possible but historically uncommon; a PCAC negative vote that the FDA overrides is almost unheard of in recent practice. The substance-by-substance evidence picture in this briefing is therefore the most authoritative regulatory analysis available on these seven compounds; the political question of how the panel votes against the staff recommendation runs in parallel.